Back

Vutrisiran reduces days lost to death and/or hospitalization versus placebo in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

31 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Multidisciplinary care in heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Mazen Hanna

Cleveland Clinic Main Campus, Cleveland (United States of America)

6 More presentations in this session

Presentation thumbnail
Impact of QRS duration on drug titration and left ventricular recovery in new-onset heart failure with reduced ejection fraction
Doctor A. Arenas Loriente (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
A decision algorithm for palliative care initiation in heart failure patients
Doctor I. Santos (Ponta Delgada, PT)
Abstract Slides Video
Presentation thumbnail
The efficacy and safety of hydroxychloroquine in patients with chronic inflammatory cardiomyopathy after fulminant myocarditis: a multicenter randomized study of the HYPIC trial
Doctor W. He (Wuhan, CN)
Abstract Slides Video
Presentation thumbnail
Effects of a dyadic empowerment-based heart failure management program (De-HF) on patient-reported and clinical outcomes: a double-blind randomized controlled trial
Doctor D. Yu (Hong Kong, HK)
Abstract Slides Video
Presentation thumbnail
Efficacy of early initiation of vericiguat in acute heart failure: a prospective study
Doctor J. Chen (Chongqing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Multidisciplinary care in heart failure

The Event

Event poster

ESC Congress 2025

31 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
HELIOS-B: Vutrisiran reduces all-cause mortality
thumbnail
Congress Presentation
HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
thumbnail
Congress Presentation
Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy in HELIOS-B who had progressed on tafamidis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources